- Report
- September 2026
- 185 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 188 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 196 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 190 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 193 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 191 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 189 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 193 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 197 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- September 2026
- 240 Pages
Global
From €5318EUR$5,850USD£4,572GBP
- Report
- September 2026
- 377 Pages
Global
From €5318EUR$5,850USD£4,572GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- February 2026
- 250 Pages
Global
From €4081EUR$4,490USD£3,509GBP
- Report
- September 2026
- 193 Pages
Global
From €3222EUR$3,545USD£2,771GBP
€3580EUR$3,939USD£3,079GBP
- Report
- May 2026
- 180 Pages
Global
From €4090EUR$4,500USD£3,517GBP
- Report
- July 2026
- 198 Pages
Global
From €7263EUR$7,990USD£6,245GBP
- Report
- May 2026
- 350 Pages
Global
From €4499EUR$4,949USD£3,868GBP
- Report
- May 2026
- 350 Pages
Global
From €4499EUR$4,949USD£3,868GBP
- Report
- August 2026
- 117 Pages
Global
From €4318EUR$4,750USD£3,712GBP

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression.
The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms.
Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more